NCT01433263View on ClinicalTrials.gov

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Cachexia
Interventions
DRUG

BYM338 active drug

DRUG

Placebo

Trial Locations (10)

9007

Novartis Investigative Site, Sankt Gallen

33647

Novartis Investigative Site, Tampa

44718

Novartis Investigative Site, Canton

78217

Novartis Investigative Site, San Antonio

85715

Novartis Investigative Site, Tucson

60611-3308

Novartis Investigative Site, Chicago

02114

Novartis Investigative Site, Boston

LT 08661

Novartis Investigative Site, Vilnius

Sector 5

Novartis Investigative Site, Bucharest

EH10 5HF

Novartis Investigative Site, Edinburgh

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY